Vitronectin

Protein
VTN
Available structures
PDBOrtholog search: PDBe RCSB
List of PDB id codes

1OC0, 1S4G, 1SSU, 2JQ8, 3BT1, 3BT2, 4K24

Identifiers
AliasesVTN, V75, VN, VNT, vitronectin
External IDsOMIM: 193190; MGI: 98940; HomoloGene: 532; GeneCards: VTN; OMA:VTN - orthologs
Gene location (Human)
Chromosome 17 (human)
Chr.Chromosome 17 (human)[1]
Chromosome 17 (human)
Genomic location for VTN
Genomic location for VTN
Band17q11.2Start28,367,284 bp[1]
End28,373,091 bp[1]
Gene location (Mouse)
Chromosome 11 (mouse)
Chr.Chromosome 11 (mouse)[2]
Chromosome 11 (mouse)
Genomic location for VTN
Genomic location for VTN
Band11 B5|11 46.74 cMStart78,389,917 bp[2]
End78,393,150 bp[2]
RNA expression pattern
Bgee
HumanMouse (ortholog)
Top expressed in
  • right lobe of liver

  • right adrenal gland

  • left adrenal gland

  • gallbladder

  • left ventricle

  • placenta

  • islet of Langerhans

  • body of pancreas

  • duodenum

  • right coronary artery
Top expressed in
  • left lobe of liver

  • gallbladder

  • optic nerve

  • retinal pigment epithelium

  • sexually immature organism

  • pia mater

  • olfactory bulb

  • ciliary body

  • supraoptic nucleus

  • superior frontal gyrus
More reference expression data
BioGPS
More reference expression data
Gene ontology
Molecular function
  • protein binding
  • scavenger receptor activity
  • heparin binding
  • extracellular matrix binding
  • polysaccharide binding
  • integrin binding
  • identical protein binding
  • collagen binding
  • extracellular matrix structural constituent
Cellular component
  • alphav-beta3 integrin-vitronectin complex
  • extracellular exosome
  • blood microparticle
  • Golgi lumen
  • basement membrane
  • rough endoplasmic reticulum lumen
  • cytoplasm
  • extracellular matrix
  • extracellular space
  • endoplasmic reticulum
  • intracellular membrane-bounded organelle
  • extracellular region
  • collagen-containing extracellular matrix
Biological process
  • receptor-mediated endocytosis
  • positive regulation of protein binding
  • cell adhesion
  • positive regulation of cell-substrate adhesion
  • extracellular matrix organization
  • smooth muscle cell-matrix adhesion
  • regulation of complement activation
  • positive regulation of smooth muscle cell migration
  • negative regulation of endopeptidase activity
  • positive regulation of peptidyl-tyrosine phosphorylation
  • positive regulation of vascular endothelial growth factor receptor signaling pathway
  • immune response
  • endodermal cell differentiation
  • positive regulation of wound healing
  • positive regulation of receptor-mediated endocytosis
  • negative regulation of blood coagulation
  • oligodendrocyte differentiation
  • cell adhesion mediated by integrin
  • cell-matrix adhesion
  • protein polymerization
  • liver regeneration
  • cell population proliferation
  • cell migration
  • vesicle-mediated transport
  • endocytosis
Sources:Amigo / QuickGO
Orthologs
SpeciesHumanMouse
Entrez

7448

22370

Ensembl

ENSG00000109072

ENSMUSG00000017344

UniProt

P04004

P29788

RefSeq (mRNA)

NM_000638

NM_011707

RefSeq (protein)

NP_000629

NP_035837

Location (UCSC)Chr 17: 28.37 – 28.37 MbChr 11: 78.39 – 78.39 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Vitronectin (VTN or VN) is a glycoprotein of the hemopexin family which is synthesized and excreted by the liver, and abundantly found in serum, the extracellular matrix and bone.[5] In humans it is encoded by the VTN gene.[6][7]

Vitronectin binds to integrin alpha-V beta-3 and thus promotes cell adhesion and spreading. It also inhibits the membrane-damaging effect of the terminal cytolytic complement pathway and binds to several serpins (serine protease inhibitors). It is a secreted protein and exists in either a single chain form or a clipped, two chain form held together by a disulfide bond.[6] Vitronectin has been speculated to be involved in hemostasis[8] and tumor malignancy.[9][10]

Structure

Vitronectin is a 54 kDa glycoprotein, consisting of 478 amino acid residues. About one-third of the protein's molecular mass is composed of carbohydrates. On occasion, the protein is cleaved after arginine 379, to produce two-chain vitronectin, where the two parts are linked by a disulfide bond. No high-resolution structure has been determined experimentally yet, except for the N-terminal domain.

The protein consists of three domains:

Several structures has been reported for the Somatomedin B domain. The protein was initially crystallized in complex with one of its physiological binding partners: the Plasminogen activator inhibitor-1 (PAI-1) and the structure solved for this complex.[11] Subsequently two groups reported NMR structures of the domain.[12][13]

The somatomedin B domain is a close-knit disulfide knot, with 4 disulfide bonds within 35 residues. Different disulfide configurations had been reported for this domain[14][15][16] but this ambiguity has been resolved by the crystal structure.[16]

Homology models have been built for the central and C-terminal domains.[16]

Function

The somatomedin B domain of vitronectin binds to plasminogen activator inhibitor-1 (PAI-1), and stabilizes it.[11] Thus vitronectin serves to regulate proteolysis initiated by plasminogen activation. In addition, vitronectin is a component of platelets and is, thus, involved in hemostasis. Vitronectin contains an RGD (45-47) sequence, which is a binding site for membrane-bound integrins, e.g., the vitronectin receptor, which serve to anchor cells to the extracellular matrix. The Somatomedin B domain interacts with the urokinase receptor, and this interaction has been implicated in cell migration and signal transduction. High plasma levels of both PAI-1 and the urokinase receptor have been shown to correlate with a negative prognosis for cancer patients. Cell adhesion and migration are directly involved in cancer metastasis, which provides a probable mechanistic explanation for this observation.

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000109072 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000017344 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Boron, Walter F. and Boulpaep, Emile L. "Medical Physiology". Saunders, 2012, p.1097.
  6. ^ a b "Entrez Gene: M Vitronectin".
  7. ^ Jenne D, Stanley KK (Oct 1987). "Nucleotide sequence and organization of the human S-protein gene: repeating peptide motifs in the "pexin" family and a model for their evolution". Biochemistry. 26 (21): 6735–42. doi:10.1021/bi00395a024. PMID 2447940.
  8. ^ Preissner KT, Seiffert D (Jan 1998). "Role of vitronectin and its receptors in haemostasis and vascular remodeling". Thrombosis Research. 89 (1): 1–21. doi:10.1016/S0049-3848(97)00298-3. PMID 9610756.
  9. ^ Felding-Habermann B, Cheresh DA (Oct 1993). "Vitronectin and its receptors". Current Opinion in Cell Biology. 5 (5): 864–8. doi:10.1016/0955-0674(93)90036-P. PMID 7694604.
  10. ^ Hurt, Elaine M.; Chan, King; Serrat, Maria Ana Duhagon; Thomas, Suneetha B.; Veenstra, Timothy D.; Farrar, William L. (2009). "Identification of Vitronectin as an Extrinsic Inducer of Cancer Stem Cell Differentiation and Tumor Formation". Stem Cells. 28 (3): 390–8. doi:10.1002/stem.271. PMC 3448441. PMID 19998373.
  11. ^ a b Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ (Jul 2003). "How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration". Nature Structural Biology. 10 (7): 541–4. doi:10.1038/nsb943. PMID 12808446. S2CID 26086796.
  12. ^ Kamikubo Y, De Guzman R, Kroon G, Curriden S, Neels JG, Churchill MJ, Dawson P, Ołdziej S, Jagielska A, Scheraga HA, Loskutoff DJ, Dyson HJ (Jun 2004). "Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin". Biochemistry. 43 (21): 6519–34. doi:10.1021/bi049647c. PMID 15157085.
  13. ^ Mayasundari A, Whittemore NA, Serpersu EH, Peterson CB (Jul 2004). "The solution structure of the N-terminal domain of human vitronectin: proximal sites that regulate fibrinolysis and cell migration". The Journal of Biological Chemistry. 279 (28): 29359–66. doi:10.1074/jbc.M401279200. PMID 15123712.
  14. ^ Kamikubo Y, Okumura Y, Loskutoff DJ (Jul 2002). "Identification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectin". The Journal of Biological Chemistry. 277 (30): 27109–19. doi:10.1074/jbc.M200354200. PMID 12019263.
  15. ^ Horn NA, Hurst GB, Mayasundari A, Whittemore NA, Serpersu EH, Peterson CB (Aug 2004). "Assignment of the four disulfides in the N-terminal somatomedin B domain of native vitronectin isolated from human plasma". The Journal of Biological Chemistry. 279 (34): 35867–78. doi:10.1074/jbc.M405716200. PMID 15173163.
  16. ^ a b c Xu D, Baburaj K, Peterson CB, Xu Y (Aug 2001). "Model for the three-dimensional structure of vitronectin: predictions for the multi-domain protein from threading and docking". Proteins. 44 (3): 312–20. doi:10.1002/prot.1096. PMID 11455604. S2CID 24765480.

Further reading

  • Singh B, Su YC, Riesbeck K (2010). "Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion". Mol. Microbiol. 78 (3): 545–60. doi:10.1111/j.1365-2958.2010.07373.x. PMID 20807208. S2CID 24516528.
  • Singh B, Jalalvand F, Mörgelin M, Zipfel P, Blom AM, Riesbeck K (2011). "Haemophilus influenzae protein E recognizes the C-terminal domain of vitronectin and modulates the membrane attack complex". Mol. Microbiol. 81 (1): 80–98. doi:10.1111/j.1365-2958.2011.07678.x. PMID 21542857. S2CID 26484037.
  • Su YC, Jalalvand F, Mörgelin M, Blom AM, Singh B, Riesbeck K (2013). "Haemophilus influenzae acquires vitronectin via the ubiquitous Protein F to subvert host innate immunity". Mol. Microbiol. 87 (6): 1245–66. doi:10.1111/mmi.12164. PMID 23387957. S2CID 26923730.

External links

  • v
  • t
  • e
  • 1oc0: PLASMINOGEN ACTIVATOR INHIBITOR-1 COMPLEX WITH SOMATOMEDIN B DOMAIN OF VITRONECTIN
    1oc0: PLASMINOGEN ACTIVATOR INHIBITOR-1 COMPLEX WITH SOMATOMEDIN B DOMAIN OF VITRONECTIN
  • 1s4g: Somatomedin-B Domain of human plasma vitronectin.
    1s4g: Somatomedin-B Domain of human plasma vitronectin.
  • 1ssu: Structural and biochemical evidence for disulfide bond heterogeneity in active forms of the somatomedin B domain of human vitronectin
    1ssu: Structural and biochemical evidence for disulfide bond heterogeneity in active forms of the somatomedin B domain of human vitronectin
  • v
  • t
  • e
Mucoproteins
Mucin
Other
Proteoglycans
CS/DS
HS/CS
CS
KS
HS
Other
  • v
  • t
  • e
Extracellular
matrix
Collagen
Fibril forming
Other
Enzymes
Laminin
Other
Other